Unicycive Therapeutics, Inc.
UNCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001766140
No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Unicycive Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 10 | 12 | +2 |
| Shares | 1.07M | 1.12M | +49.8K (+4.7%) |
| Value | $3.02M | $2.30M | −$717.0K (−23.8%) |
New holders (4)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ayrton Capital LLC | 76,645 | $158.0K | 0.15% |
| Vanguard Group Inc | 22,695 | $47.0K | 0.00% |
| Bank of America Corp | 21 | $0 | 0.00% |
| Morgan Stanley | 2 | $0 | 0.00% |
Sold out (2)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Two Sigma Investments, LP | 25,551 | $72.0K |
| Sanders Morris Harris LLC | 20,000 | $57.0K |